Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

News SummaryMost relevantAll newsSector news 

AstraZeneca plc : AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S

share with twitter share with LinkedIn share with facebook
share via e-mail
07/25/2013 | 02:26pm CET

AstraZeneca and Bristol-Myers Squibb today announced they have resubmitted to the U.S. Food and Drug Administration (FDA), a New Drug Application (NDA) for dapagliflozin for the treatment of adults with type 2 diabetes.

The NDA resubmission, which is pending acceptance by the FDA, includes several new studies and additional long-term data (up to four years' duration) from previously submitted studies.

NOTES TO EDITORS About dapagliflozin

Dapagliflozin, an investigational compound, is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), which works independently of insulin. It is currently approved for the treatment of type 2 diabetes in the European Union, Australia, Brazil, Mexico and New Zealand.

About Type 2 Diabetes

In 2012, diabetes was estimated to affect more than 370 million people worldwide. The prevalence of diabetes is projected to reach more than 550 million by 2030. Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. Type 2 diabetes is a chronic disease characterised by insulin resistance and dysfunction of beta cells in the pancreas, leading to elevated glucose levels. Over time, this sustained hyperglycemia contributes to further progression of the disease. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.www.astrazeneca.com

CONTACTS Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Vanessa Rhodes +44 20 7604 8037 (UK/Global)
Ayesha Bharmal +44 20 7604 8034 (UK/Global)
Michele Meixell +1 302 885 2677 (US)
Jacob Lund +46 8 553 260 20 (Sweden)

Colleen Proctor + 44 207 604 8128 mob: +1 302 357 4882
Ed Seage + 44 207 604 8125 mob: +1 302 373 1361

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
06:46p FTSE records best week since July, Sky surges 27 percent on Fox bid
05:00p ASTRAZENECA : US FDA accepts first biologics license application for AstraZeneca..
04:31pDJASTRAZENECA : FDA Accepts License Application for Durvalumab
04:24p TOP NEWS : AstraZeneca Receives FDA Priority Status For Durvalumab
04:21p ASTRAZENECA : FDA accepts durvalumab for BLA in bladder cancer
02:04p ASTRAZENECA PLC (NYSE : AZN) Cuts Jobs, Signs New Collaboration With Eli Lilly a..
12/08 ASTRAZENECA : cuts 700 U.S. jobs, including at its headquarters in Wilmington
12/08 ASTRAZENECA : cuts about 700 jobs, including 120 in Delaware
12/08 ASTRAZENECA : Tagrisso shows promise in treating form of advanced lung cancer
12/08 ASTRAZENECA : Announces Subgroup Analysis from FALCON Trial Comparing FASLODEX® ..
More news
Sector news : Pharmaceuticals - NEC
06:46p FTSE records best week since July, Sky surges 27 percent on Fox bid
02:05pDJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:59p CANCER IMMUNOTHERAPY MARKET : 2016 Takeaways And What To Expect In 2017
12:24p FDA accepts AstraZeneca's marketing application for durvalumab for bladder ca..
09:58a Trading in AstraZeneca halted pending news
07:47a Lilly not giving up on Alzheimer's, teams up with AstraZeneca to develop earl..
12/08 New Oral Psoriasis Drug Tops Cellceutix Catalysts
Financials ($)
Sales 2016 22 930 M
EBIT 2016 6 492 M
Net income 2016 2 406 M
Debt 2016 11 470 M
Yield 2016 5,36%
P/E ratio 2016 25,57
P/E ratio 2017 23,99
EV / Sales 2016 3,37x
EV / Sales 2017 3,58x
Capitalization 65 712 M
More Financials
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 64,7 $
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-12.54%65 712
JOHNSON & JOHNSON8.05%301 952
ROCHE HOLDING LTD.-19.97%189 184
PFIZER INC.-3.38%187 755
NOVARTIS AG-20.79%178 671
MERCK & CO., INC.13.82%165 759
More Results